Arabic Arabic English English French French German German
dark

SNIPR BIOME Announces FDA Clearance of Investigational New Drug (IND) Application for SNIPR001, a Novel CRISPR Therapy Targeting Life-Threatening E. coli Infections

SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, is pleased to announce that the US Food and Drug Administration has approved the Investigational New Drug Application, for our first development candidate, enabling the company to initiate the first clinical trial in humans with SNIPR001. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

AlzeCure gets Late Breaking Abstract Accepted on NeuroRestore’s Positive Effect on Mitochondrial Function

Next Post

Avinger Announces 510(k) Clearance for Lightbox 3 Next-Generation Imaging Console

Related Posts
Total
0
Share